Stephens Consulting LLC Grows Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Stephens Consulting LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 325.0% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 340 shares of the biopharmaceutical company’s stock after purchasing an additional 260 shares during the period. Stephens Consulting LLC’s holdings in Gilead Sciences were worth $31,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of GILD. FMR LLC raised its holdings in Gilead Sciences by 79.4% in the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock worth $2,780,329,000 after purchasing an additional 14,680,161 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Gilead Sciences by 50.9% in the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock worth $2,900,921,000 after buying an additional 11,665,593 shares during the last quarter. Pacer Advisors Inc. raised its stake in shares of Gilead Sciences by 723.3% during the 4th quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company’s stock worth $594,370,000 after acquiring an additional 5,653,075 shares in the last quarter. Point72 Asset Management L.P. lifted its position in Gilead Sciences by 350.1% during the third quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company’s stock valued at $193,274,000 after acquiring an additional 1,793,145 shares during the last quarter. Finally, International Assets Investment Management LLC boosted its stake in Gilead Sciences by 8,238.4% in the third quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company’s stock valued at $137,708,000 after acquiring an additional 1,622,806 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $98.38 on Tuesday. The stock has a market cap of $122.61 billion, a P/E ratio of 1,093.11, a P/E/G ratio of 1.37 and a beta of 0.18. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $99.45. The stock has a 50 day moving average of $92.42 and a two-hundred day moving average of $85.96. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. During the same period in the previous year, the company posted $2.29 EPS. The company’s quarterly revenue was up 7.0% on a year-over-year basis. On average, research analysts forecast that Gilead Sciences, Inc. will post 4.34 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on GILD. Citigroup started coverage on Gilead Sciences in a report on Thursday, November 14th. They set a “buy” rating and a $125.00 price objective for the company. Piper Sandler raised their price target on Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. The Goldman Sachs Group upped their price objective on shares of Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a report on Thursday, November 7th. Truist Financial lifted their target price on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research note on Friday, November 8th. Finally, Leerink Partners upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and upped their price target for the company from $74.00 to $96.00 in a research note on Monday, October 21st. Eleven investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $98.39.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the transaction, the director now directly owns 8,920 shares in the company, valued at $815,198.80. This represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 598,414 shares of company stock worth $55,953,200. 0.29% of the stock is currently owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.